PRESS-RELEASE ·Filed May 8, 2026
Press release · Earnings
Actionable Insight • Neutral
Cash runway into Q4 2026 suggests no near-term dilution risk, but the company will likely need to raise capital before mid-2027.
Final — all horizons settled through T+60d
TVRD ▼ -51.44% at T+60d
NEUTRAL call -51.44% · α vs SPY -56.27% · entry $4.18 → $2.03
T+1d
-5.26%
call -5.26% · α -5.50%
$3.96
settled 6mo ago
T+5d
-5.26%
call -5.26% · α -6.73%
$3.96
settled 6mo ago
T+20d
-30.86%
call -30.86% · α -30.88%
$2.89
settled 5mo ago
T+60d
-51.44%
call -51.44% · α -56.27%
$2.03
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Tvardi Therapeutics reported Q1 2026 EPS of -$0.73, missing consensus of -$0.72 by 1.4% (in-line), with no revenue. The company highlighted upcoming catalysts: TTI-109 Phase 1 healthy volunteer data expected in June 2026 and TTI-101 Phase 2 HCC topline data in 2H 2026.
Key Financial Metrics
EPS
−$0.73
est −$0.72 · -1.4%
Rating
in line
Key Facts
- Q1 2026 EPS: -$0.73 vs consensus -$0.72 (1.4% miss, in-line)
- No revenue reported (pre-revenue clinical-stage biotech)
- Net loss of $6.8M vs $9.6M in Q1 2025 (improved due to prior year's $5.5M other expense)
- Operating expenses increased to $7.1M from $4.4M (R&D up 58%, G&A up 72%)
- Cash and short-term investments: $25.0M as of March 31, 2026, down from $30.8M at Dec 31, 2025
- Cash runway sufficient through Q4 2026
- TTI-109 Phase 1 healthy volunteer topline data expected June 2026
- TTI-101 Phase 2 HCC topline data expected 2H 2026
Financial Impact
Net loss of $6.8M in Q1 2026; cash burn of ~$5.8M per quarter; $25.0M cash runway into Q4 2026
epscashoperating expenses
Risk Factors
- TTI-109 or TTI-101 clinical trial failures could severely impact stock price
- Cash runway only through Q4 2026; likely need for additional financing
- No revenue and increasing operating expenses
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290997 |
10 reports for TVRD
60% Hit rate @ T+20 Went positive at some point 4 of 5 best @ T+1▲ +61.29%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | Institutional Cluster | $1.86 $1.61 | ▲ +13.44% | ▲ +12.91% | $0.8420 (+54.73%) |
Aug 14, 2026 10w ago | 8-K | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8420 (−55.68%) |
Aug 14, 2026 10w ago | Press Release | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8420 (−55.68%) |
Jul 30, 2026 12w ago | 8-K | $2.10 $1.80 | ▼ −14.29% | ▼ −18.25% | $0.8420 (−59.90%) |
Jul 7, 2026 15w ago | 8-K | $3.10 $2.02 | ▼ −34.84% | ▼ −36.17% | $0.8420 (−72.84%) |
May 14, 2026 23w ago | EFFECT | $3.96 $2.64 | ▲ +33.33% | ▲ +32.48% | $0.8420 (+78.74%) |
May 13, 2026 23w ago | EFFECT | $3.95 $2.71 | ▲ +31.39% | ▲ +30.78% | $0.8420 (+78.68%) |
May 8, 2026 24w ago | Press Release | $4.18 $2.89 | ▼ −30.86% | ▼ −30.88% | $0.8420 (−79.86%) |
Apr 23, 2026 26w ago | DEFA14A | $3.10 $3.59 | ▲ +15.81% | ▲ +11.78% | $0.8420 (−72.84%) |
Mar 31, 2026 29w ago | 8-K | $3.00 $3.06 | ▲ +2.00% | ▼ −7.72% | $0.8420 (−71.93%) |
Showing 10 of 10
US Market Status
Market Closed — Opens in 4h 9m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers